ArabinoFuranosylGuanine [18F]F-AraG

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Advanced CancerClear Cell Renal Cell CarcinomaEsophageal Cancer

Phase 1

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

RecruitingNCT05663710

M.D. Anderson Cancer CenterAdvanced Cancer, Clear Cell Renal Cell Carcinoma

Start: 2023-06-30End: 2027-10-30Target: 100Updated: 2026-07-30

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

RecruitingNCT06414902

M.D. Anderson Cancer CenterEsophageal Cancer

Start: 2024-09-04End: 2027-10-01Target: 60Updated: 2026-05-19

Related Papers

STARLITE-1: Phase 1b/2 study of combination <sup>177</sup> Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.

Journal of Clinical Oncology2025-05-28

Phase 1b/2 study of combination <sup>177</sup> Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.

Journal of Clinical Oncology2025-02-10

Phase 1b/2 study of combination <sup>177</sup>Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.

Journal of Clinical Oncology2024-06-012 citations